Current status on the development of pseudoviruses for enveloped viruses
Tóm tắt
Emerging and reemerging infectious diseases have a strong negative impact on public health. However, because many of these pathogens must be handled in biosafety level, 3 or 4 containment laboratories, research and development of antivirals or vaccines against these diseases are often impeded. Alternative approaches to address this issue have been vigorously pursued, particularly the use of pseudoviruses in place of wild‐type viruses. As pseudoviruses have been deprived of certain gene sequences of the virulent virus, they can be handled in biosafety level 2 laboratories. Importantly, the envelopes of these viral particles may have similar conformational structures to those of the wild‐type viruses, making it feasible to conduct mechanistic investigation on viral entry and to evaluate potential neutralizing antibodies. However, a variety of challenging issues remain, including the production of a sufficient pseudovirus yield and the inability to produce an appropriate pseudotype of certain viruses. This review discusses current progress in the development of pseudoviruses and dissects the factors that contribute to low viral yields.
Từ khóa
Tài liệu tham khảo
Clapham PR, 1992, Vesicular stomatitis virus pseudotypes of retroviruses, Methods Mol Biol, 8, 95
Zhang L, 2017, A bioluminescent imaging mouse model for Marburg virus based on a pseudovirus system, Hum Vaccin Immunother, 13, 1, 10.1080/21645515.2017.1325050
Robinson JE, 2016, Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits, Nat Commun, 7, 11,544, 10.1038/ncomms11544
Nie J, 2017, Development of in vitro and in vivo rabies virus neutralization assays based on a high‐titer pseudovirus system, Sci Rep, 7, 42,769, 10.1038/srep42769
Nie J, 2016, Development of a triple‐color pseudovirion‐based assay to detect neutralizing antibodies against human papillomavirus, Virus, 8, 107, 10.3390/v8040107
Mattia K, 2011, Dengue reporter virus particles for measuring neutralizing antibodies against each of the four dengue serotypes, PLoS One, 6, e27252, 10.1371/journal.pone.0027252
Kishishita N, 2013, Development of a pseudotyped‐lentiviral‐vector‐based neutralization assay for chikungunya virus infection, J Clin Microbiol, 51, 1389, 10.1128/JCM.03109-12
Hu D, 2014, Chikungunya virus glycoproteins pseudotype with lentiviral vectors and reveal a broad spectrum of cellular tropism, PLoS One, 9, e110893, 10.1371/journal.pone.0110893
Barrientos LG, 2004, In vitro evaluation of cyanovirin‐N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins, J Infect Dis, 189, 1440, 10.1086/382658
Chong H, 2009, Mutation L33M in the HR1 region of HIV‐1 gp41 may play a role in T20 resistance, J Clin Virol, 45, 255, 10.1016/j.jcv.2009.05.001
Wang W, 2013, A systematic study of the N‐glycosylation sites of HIV‐1 envelope protein on infectivity and antibody‐mediated neutralization, Retrovirology, 10, 14, 10.1186/1742-4690-10-14
Klewitz C, 2007, Amino acids from both N‐terminal hydrophobic regions of the Lassa virus envelope glycoprotein GP‐2 are critical for pH‐dependent membrane fusion and infectivity, J Gen Virol, 88, 2320, 10.1099/vir.0.82950-0
Grehan K, 2015, An optimised method for the production of MERS‐CoV spike expressing viral pseudotypes, MethodsX, 2, 379, 10.1016/j.mex.2015.09.003
Yang Y, 2014, Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat‐to‐human transmission of MERS coronavirus, Proc Natl Acad Sci U S A, 111, 12,516, 10.1073/pnas.1405889111
Kahl CA, 2004, Human immunodeficiency virus type 1‐derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus, J Virol, 78, 1421, 10.1128/JVI.78.3.1421-1430.2004
Haid S, 2015, Identification of a human respiratory syncytial virus cell entry inhibitor by using a novel Lentiviral pseudotype system, J Virol, 90, 3065, 10.1128/JVI.03074-15
Ao Z, 2008, Characterization of a trypsin‐dependent avian influenza H5N1‐pseudotyped HIV vector system for high throughput screening of inhibitory molecules, Antiviral Res, 79, 12, 10.1016/j.antiviral.2008.02.001
Guo Y, 2009, Analysis of hemagglutinin‐mediated entry tropism of H5N1 avian influenza, Virol J, 6, 39, 10.1186/1743-422X-6-39
Ferrara F, 2012, The human transmembrane protease serine 2 is necessary for the production of group 2 influenza A virus pseudotypes, J Mol Genet Med, 7, 309
Bosch V, 1990, Mutational analysis of the human immunodeficiency virus type 1 env gene product proteolytic cleavage site, J Virol, 64, 2337, 10.1128/jvi.64.5.2337-2344.1990
Liu Q, 2017, Antibody‐dependent‐cellular‐cytotoxicity‐inducing antibodies significantly affect the post‐exposure treatment of Ebola virus infection, Sci Rep, 7, 45,552, 10.1038/srep45552
Moore MJ, 2004, Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin‐converting enzyme 2, J Virol, 78, 10,628, 10.1128/JVI.78.19.10628-10635.2004
Jia HP, 2005, ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia, J Virol, 79, 14,614, 10.1128/JVI.79.23.14614-14621.2005
Mendenhall A, 2012, Packaging HIV‐ or FIV‐based lentivector expression constructs and transduction of VSV‐G pseudotyped viral particles, J Vis Exp, e3171
Stillman EA, 1995, Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins, J Virol, 69, 2946, 10.1128/jvi.69.5.2946-2953.1995
Schnell MJ, 1996, Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles, Proc Natl Acad Sci U S A, 93, 11,359, 10.1073/pnas.93.21.11359
Moeschler S, 2016, Quantification of lyssavirus‐neutralizing antibodies using vesicular stomatitis virus pseudotype particles, Virus, 8
Kaku Y, 2012, Second generation of pseudotype‐based serum neutralization assay for Nipah virus antibodies: sensitive and high‐throughput analysis utilizing secreted alkaline phosphatase, J Virol Methods, 179, 226, 10.1016/j.jviromet.2011.11.003
Takada A, 1997, A system for functional analysis of Ebola virus glycoprotein, Proc Natl Acad Sci U S A, 94, 14,764, 10.1073/pnas.94.26.14764
Quinn K, 2009, Rho GTPases modulate entry of Ebola virus and vesicular stomatitis virus pseudotyped vectors, J Virol, 83, 10,176, 10.1128/JVI.00422-09
Ogino M, 2003, Use of vesicular stomatitis virus pseudotypes bearing Hantaan or Seoul virus envelope proteins in a rapid and safe neutralization test, Clin Diagn Lab Immunol, 10, 154
Lee BH, 2006, A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice, Vaccine, 24, 2928, 10.1016/j.vaccine.2005.12.040
Ray N, 2010, Study of Andes virus entry and neutralization using a pseudovirion system, J Virol Methods, 163, 416, 10.1016/j.jviromet.2009.11.004
Higa MM, 2012, Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies, Virology, 423, 134, 10.1016/j.virol.2011.08.012
Kunz S, 2005, Characterization of the interaction of Lassa fever virus with its cellular receptor alpha‐dystroglycan, J Virol, 79, 5979, 10.1128/JVI.79.10.5979-5987.2005
Tong W, 2015, Preparation of vesicular stomatitis virus pseudotype with Chikungunya virus envelope protein, Acta Virol, 59, 189, 10.4149/av_2015_02_189
Zimmer G, 2014, Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses, J Gen Virol, 95, 1634, 10.1099/vir.0.065201-0
Cheresiz SV, 2014, A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus, Arch Virol, 159, 2651, 10.1007/s00705-014-2127-y
Wool‐Lewis RJ, 1998, Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor‐deficient cell lines, J Virol, 72, 3155, 10.1128/JVI.72.4.3155-3160.1998
Hohne M, 1999, Truncation of the human immunodeficiency virus‐type‐2 envelope glycoprotein allows efficient pseudotyping of murine leukemia virus retroviral vector particles, Virology, 261, 70, 10.1006/viro.1999.9847
Siegert S, 2005, Assessment of HIV‐1 entry inhibitors by MLV/HIV‐1 pseudotyped vectors, AIDS Res Ther, 2, 7, 10.1186/1742-6405-2-7
Bruett L, 2001, Functional murine leukemia virus vectors pseudotyped with the visna virus envelope show expanded visna virus cell tropism, J Virol, 75, 11,464, 10.1128/JVI.75.23.11464-11473.2001
Han DP, 2004, Development of a safe neutralization assay for SARS‐CoV and characterization of S‐glycoprotein, Virology, 326, 140, 10.1016/j.virol.2004.05.017
Kines KJ, 2006, Transduction of Schistosoma mansoni by vesicular stomatitis virus glycoprotein‐pseudotyped Moloney murine leukemia retrovirus, Exp Parasitol, 112, 209, 10.1016/j.exppara.2006.02.003
Yang S, 2010, Transduction of Schistosoma Japonicum schistosomules with vesicular stomatitis virus glycoprotein pseudotyped murine leukemia retrovirus and expression of reporter human telomerase reverse transcriptase in the transgenic schistosomes, Mol Biochem Parasitol, 174, 109, 10.1016/j.molbiopara.2010.07.007
Wallerstrom S, 2014, Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests, Infect Ecol Epidemiol, 4
Witte ON, 1977, Mechanism of formation of pseudotypes between vesicular stomatitis virus and murine leukemia virus, Cell, 11, 505, 10.1016/0092-8674(77)90068-X
Cosset FL, 2009, Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles, J Virol, 83, 3228, 10.1128/JVI.01711-08
Scott SD, 2016, The optimisation of pseudotyped viruses for the characterisation of immune responses to equine influenza virus, Pathogens, 5, 10.3390/pathogens5040068
Steffen I, 2016, Pseudotyping viral vectors with emerging virus envelope proteins, Curr Gene Ther, 16, 47, 10.2174/1566523216666160119093948
Wilkinson DE, 2017, Comparison of platform technologies for assaying antibody to Ebola virus, Vaccine, 35, 1347, 10.1016/j.vaccine.2016.11.083
Duehr J, 2017, Novel cross‐reactive monoclonal antibodies against Ebola virus glycoproteins show protection in a murine challenge model, J Virol, 91, e00652, 10.1128/JVI.00652-17
Basu A, 2010, High‐throughput screening of viral entry inhibitors using pseudotyped virus, Curr Protoc Pharmacol, 10.1002/0471141755.ph13b03s51
Zeilfelder U, 2001, Properties of wild‐type, C‐terminally truncated, and chimeric maedi‐visna virus glycoprotein and putative pseudotyping of retroviral vector particles, J Virol, 75, 548, 10.1128/JVI.75.1.548-555.2001